Back to Agenda
From Breakthrough to Life: Engineered T Cells, Patients, and the Future of Biotech
Session Chair(s)
Katie Truong
SVP & Managing Director, DIA Americas and Global Head of Business Operations
DIA, United States
This fireside chat traces CAR T’s path from bold experiment to standard of care and catalyst for a new era of biotech innovation. Through scientific, policy, and patient perspectives, speakers will explore what it takes to translate high risk science into sustainable therapies and what CAR T’s journey signals for the future of regulators, payers, sponsors, and technology partners in advanced therapies.
Learning Objective : Describe how advances in engineered T cells, including CAR-T, are reshaping expectations for cancer treatment and the broader biotech pipeline; Identify scientific, regulatory, and system conditions needed to translate high-risk engineered T-cell innovations into equitable, scalable patient benefit; Discuss how real patient and family experiences inform future strategies for regulators, payers, sponsors, and technology partners developing next-generation cell therapies.
Speaker(s)
Plenary Presenter
Bruce Levine
Perelman School of Medicine at the University of Pennsylvania, United States
Founding Director, Clinical Cell and Vaccine Production Facility (CVPF)
Panelist
Bradley Watts
Connor, Strong, and Buckelew, United States
Vice President, Business Development Executive
Have an account?